Form 8-K - Current report:
SEC Accession No. 0000926617-23-000024
Filing Date
2023-03-30
Accepted
2023-03-30 07:44:55
Documents
16
Period of Report
2023-03-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K awh-20230328x8k.htm   iXBRL 8-K 90044
2 EX-5.1 awh-20230328xex5_1.htm EX-5.1 18196
3 EX-10.1 awh-20230328xex10_1.htm EX-10.1 341355
4 EX-10.2 awh-20230328xex10_2.htm EX-10.2 192751
5 GRAPHIC awh-20230328xex5_1g001.jpg GRAPHIC 24621
  Complete submission text file 0000926617-23-000024.txt   896957

Data Files

Seq Description Document Type Size
6 EX-101.SCH awh-20230328.xsd EX-101.SCH 2550
7 EX-101.LAB awh-20230328_lab.xml EX-101.LAB 15612
8 EX-101.PRE awh-20230328_pre.xml EX-101.PRE 11194
10 EXTRACTED XBRL INSTANCE DOCUMENT awh-20230328x8k_htm.xml XML 5016
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34810 | Film No.: 23777175
SIC: 2835 In Vitro & In Vivo Diagnostic Substances